Cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.10-29, 2012. ,
DOI : 10.3322/caac.20138
Androgen receptor outwits prostate cancer drugs, Nature Medicine, vol.10, issue.1, pp.26-27, 2004. ,
DOI : 10.1038/nm0104-26
A history of prostate cancer treatment, 2002. ,
New therapies for, 2011. ,
The development of androgen-independent prostate cancer, Nature Reviews Cancer, vol.1, issue.1, pp.34-45, 2001. ,
DOI : 10.1038/35094009
Transdifferentiation of prostate cancer cells to &+'" a neuroendocrine cell phenotype in vitro and in vivo, The Journal of urology, vol.162, pp.1800-1805, 1999. ,
Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells, Molecular Endocrinology, vol.17, issue.9, pp.1726-1737, 2003. ,
DOI : 10.1210/me.2003-0031
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells, Endocrine Related Cancer, vol.13, issue.1, 2006. ,
DOI : 10.1677/erc.1.01043
Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma, The Prostate, vol.277, issue.3, pp.227-234, 2006. ,
DOI : 10.1002/pros.20338
Neuroendocrine Differentiation in Prostatic Carcinoma During Hormonal Treatment, Urology, vol.51, issue.4, pp.585-589, 1998. ,
DOI : 10.1016/S0090-4295(97)00684-5
The emergence of &#(" protocadherin-PC expression during the acquisition of apoptosis-resistance by &#)" prostate cancer cells, Oncogene, vol.21, pp.7861-7871, 2002. ,
A human-and male-specific &$%" protocadherin that acts through the wnt signaling pathway to induce &$&" neuroendocrine transdifferentiation of prostate cancer cells, Cancer research, vol.65, pp.5263-5271, 2005. ,
URL : https://hal.archives-ouvertes.fr/inserm-00106398
LNCaP model of human prostatic carcinoma, Cancer &$, vol.43, pp.1809-1818, 1983. ,
Protocadherin-PC &%#" promotes androgen-independent prostate cancer cell growth. The Prostate 66, pp.1100-1113, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00106397
An Androgen Response Element in a Far Upstream Enhancer Region Is Essential for High, Androgen-Regulated Activity of the Prostate-Specific Antigen Promoter, Molecular Endocrinology, vol.11, issue.2, pp.148-161, 1997. ,
DOI : 10.1210/mend.11.2.9883
Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects, The Prostate, vol.5, issue.1, pp.99-110, 1988. ,
DOI : 10.1002/pros.2990120112
Molecular characterization of &&%" neuroendocrine prostate cancer and identification of new drug targets, Cancer &&&, vol.1, pp.487-495, 2011. ,
Increased expression of &&)" class III beta-tubulin in castration-resistant human prostate cancer, British journal &&*, vol.101, pp.951-956, 2009. ,
The &'!" human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model &'#" for the study of androgen sensitivity. The Journal of steroid biochemistry and, pp.207-214, 1991. ,
Myc confers &')" androgen-independent prostate cancer cell growth. The Journal of clinical, pp.1724-1731, 2003. ,
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens, The Journal of Steroid Biochemistry and Molecular Biology, vol.41, issue.3-8, pp.665-669, 1992. ,
DOI : 10.1016/0960-0760(92)90401-4
Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor, Journal of Biological Chemistry, vol.277, issue.29, pp.26321-26326, 2002. ,
DOI : 10.1074/jbc.M203310200
Complex regulation of human &), p.26, 2006. ,
A new human &)(" prostate carcinoma cell line, 22Rv1, In Vitro Cell Dev Biol Anim, vol.35, pp.403-409, 1999. ,
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models, The Prostate, vol.62, issue.4, pp.249-257, 2003. ,
DOI : 10.1002/pros.10199
Differential effects of prostate cancer '++" therapeutics on neuroendocrine transdifferentiation. Molecular cancer, pp.659-669, 2008. ,
Phorbol ester- '+$" induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen- '+%" sensitive prostate cancer cells, Cell Growth Differ, vol.5, pp.735-741, 1994. ,
Ceramide accumulation is '+(" 27 independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells, pp.363-370, 2002. ,
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases: Lessons from a Rapid Autopsy Program, Cancer Research, vol.64, issue.24, pp.9209-9216, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-2442
Comprehensive expression analysis of l-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors, Human Pathology, vol.38, issue.1, pp.161-170, 2007. ,
DOI : 10.1016/j.humpath.2006.07.003
Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells*1, Human Pathology, vol.26, issue.2, pp.167-170, 1995. ,
DOI : 10.1016/0046-8177(95)90033-0
Implication of cell kinetic changes during '#'" the progression of human prostatic cancer. Clinical cancer research : an official '#, journal of the American Association for Cancer Research, vol.1, pp.473-480, 1995. ,
Molecular determinants of resistance to antiandrogen therapy, Nature Medicine, vol.10, issue.1, pp.33-39, 2004. ,
DOI : 10.1038/nm972
Androgen Receptor in Prostate Cancer, Endocrine Reviews, vol.25, issue.2, 2004. ,
DOI : 10.1210/er.2002-0032
Pathology reporting of '$&" neuroendocrine tumors: application of the Delphic consensus process to the '$'" development of a minimum pathology data set. The American journal of surgical '$, pp.300-313, 2010. ,
Immunohistochemical analysis of the '$*" proliferative activity of neuroendocrine tumors from various organs. Are there '%+" indications for a neuroendocrine tumor-carcinoma sequence? Virchows Archiv, pp.86-91, 2001. ,
Small cell carcinoma of the prostate. A '%$" morphologic and immunohistochemical study of 95 cases. The American journal, pp.65-71, 2008. ,
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant, Journal of Clinical Investigation, vol.120, issue.8, pp.2715-2730, 2010. ,
DOI : 10.1172/JCI41824DS1
Ligand-independent androgen receptor, p.29, 2009. ,
An integrated network of androgen receptor, polycomb, and '&*" TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer cell 17, pp.443-454, 2010. ,
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer, Cancer Cell, vol.19, issue.5, pp.575-586, 2011. ,
DOI : 10.1016/j.ccr.2011.04.008
NE-10 neuroendocrine cancer promotes the ''(" LNCaP xenograft growth in castrated mice, Cancer research, vol.64, pp.5489-5495, 2004. ,
Cultures of LNCaP cells were ')*" grown 24 hrs in 10% CS-FBS media supplemented or not with incremental doses of '*+" DHT. RT-PCR analysis for PCDH-PC (Left) and KLK3 (right) levels in DHT-treated over '*!" vehicle treated. (B) LNCaP cells were grown for 72h in 5% CS-FBS media then '*#" refreshed with media supplemented with 100nM DHT, and PCDH-PC as well as KLK3 '*$" levels inspected as the indicated time. (C) LNCaP cells were grown in 10% FBS in the '*%" presence or absence of bicalutamide 10 µmol/L for 10 days and mRNA levels for PCDH, Figure 2 Androgenic regulation of PC and KLK3 examined. (D) Histograms showing normalized levels of KLK2 (left), KLK3 '*'" (middle), PCDH-PC (right) from LNCaP-AI cultures treated with bicalutamide for 8 days ,
5 nmol/L docetaxel. Bars, means ± SEM of two '**" independent experiments done in triplicate. (F) Morphology of LNCaP-AI cells ,